| 2.365 -0.049 (-2.03%) | 09-09 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.99 | 1-year : | 3.15 |
| Resists | First : | 2.56 | Second : | 2.7 |
| Pivot price | 2.49  |
|||
| Supports | First : | 2.33 | Second : | 1.94 |
| MAs | MA(5) : | 2.38 |
MA(20) : | 2.5 |
| MA(100) : | 2.68 |
MA(250) : | 3.22 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 11.5  |
D(3) : | 8.8 |
| RSI | RSI(14): 37 |
|||
| 52-week | High : | 6.51 | Low : | 2.2 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ CLRB ] has closed above bottom band by 12.8%. Bollinger Bands are 42.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 39 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 2.45 - 2.47 | 2.47 - 2.48 |
| Low: | 2.32 - 2.33 | 2.33 - 2.35 |
| Close: | 2.34 - 2.37 | 2.37 - 2.39 |
Cellectar Biosciences is a biopharmaceutical firm engaged in the research, development, and market introduction of therapeutic agents to combat cancer. The company's primary asset is CLR 131 (iopofosine I-131), a phospholipid drug conjugate (PDC), which is currently undergoing several clinical evaluations. It is in Phase 2 clinical trials for individuals with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies. Additionally, CLR 131 is being studied in Phase 2B for r/r multiple myeloma (MM) and in Phase I trials targeting a range of pediatric cancers, r/r head and neck cancers, and R/R MM. Furthermore, Cellectar is advancing CLR 1900, another PDC-based chemotherapeutic program, which is in preclinical stages with the aim of treating solid tumors. The firm also participates in collaborative PDC development initiatives with partners such as Avicenna Oncology GMBH for the CLR 2000 Series, Orano Med for the CLR 12120 Series, as well as IntoCell Inc. and LegoChemBio. Established in 2002, Cellectar Biosciences maintains its corporate headquarters in Florham Park, New Jersey.
Thu, 20 Aug 2026
Cellectar Biosciences (CLRB) Q2 2026 Earnings Call Transcript - The Globe and Mail
Fri, 14 Aug 2026
Cellectar Biosciences (CLRB) investor discloses 9.99% stake and warrant holdings - Stock Titan
Thu, 13 Aug 2026
Earnings call transcript: Cellectar narrows focus on WM as Q2 2026 loss widens - Investing.com
Thu, 13 Aug 2026
Cellectar Prepares ~100-Patient-Per-Arm Trial, Plans 2027 FDA Filing - Stock Titan
Wed, 15 Jul 2026
Cellectar Biosciences Announces Publication of Phase 1 Study of Iopofosine I 131 in Peer-Reviewed Journal Cancers - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 9 (M) |
| Shares Float | 9 (M) |
| Held by Insiders | 1.7 (%) |
| Held by Institutions | 34.7 (%) |
| Shares Short | 161 (K) |
| Shares Short P.Month | 199 (K) |
| EPS | -2.22 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.61 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -58.5 % |
| Return on Equity (ttm) | -119.6 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.48 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -19 (M) |
| Levered Free Cash Flow | -13 (M) |
| PE Ratio | -1.08 |
| PEG Ratio | 0 |
| Price to Book value | 0.65 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.15 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|